Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: A randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide

Stroke

Volumn 39, Issue 1, 2008, Pages 126-131

  Lim, Jae Young ^a   Koh, Jae Hyeon ^a   Paik, Nam Jong ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Botulinum toxin a; Hemiplegia; Shoulder painstroke

Indexed keywords

BOTULINUM TOXIN A; SODIUM CHLORIDE; TRIAMCINOLONE ACETONIDE; ANTIINFLAMMATORY AGENT; NEUROTOXIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARM MOVEMENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; FUGL MEYER SCORE; HEMIPLEGIA; HUMAN; INFRASPINATUS MUSCLE; MALE; MODIFIED ASHWORTH SCALE; MUSCLE; PECTORALIS MAJOR MUSCLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; RATING SCALE; SCORING SYSTEM; SHOULDER PAIN; SPASTICITY; STROKE; SUBSCAPULARIS MUSCLE; TREATMENT OUTCOME; ADOLESCENT; COMPARATIVE STUDY; DRUG EFFECT; INTRAARTICULAR DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; JOINT CHARACTERISTICS AND FUNCTIONS; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BOTULINUM TOXIN TYPE A; DOUBLE-BLIND METHOD; FEMALE; HEMIPLEGIA; HUMANS; INJECTIONS, INTRA-ARTICULAR; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROTOXINS; RANGE OF MOTION, ARTICULAR; SHOULDER PAIN; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE;

EID: 38149142842     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.484048     Document Type: Article

References (56)

1. Aras MD, Gokkaya NK, Comert D, Kaya A, Cakci A. Shoulder pain in hemiplegia: Results from a national rehabilitation hospital in turkey. Am J Phys Med Rehabil. 2004;83:713-719.
2. Black-Schaffer RM, Kirsteins AE, Harvey RL. Stroke rehabilitation. 2. Co-morbidities and complications. Arch Phys Med Rehabil. 1999;80:S8-S16.
3. Gamble GE, Barberan E, Bowsher D, Tyrrell PJ, Jones AK. Post stroke shoulder pain: More common than previously realized. Eur J Pain. 2000;4:313-315.
4. Langhorne P, Stott DJ, Robertson L, MacDonald J, Jones L, McAlpine C, Dick F, Taylor GS, Murray G. Medical complications after stroke: A multicenter study. Stroke. 2000;31:1223-1229.
5. Lindgren I, Jonsson AC, Norrving B, Lindgren A. Shoulder pain after stroke. A prospective population-based study. Stroke. 2007;38:343-348.
6. Ratnasabapathy Y, Broad J, Baskett J, Pledger M, Marshall J, Bonita R. Shoulder pain in people with a stroke: A population-based study. Clin Rehabil. 2003;17:304-311.
7. Turner-Stokes L, Jackson D. Shoulder pain after stroke: A review of the evidence base to inform the development of an integrated care pathway. Clin Rehabil. 2002;16:276-298.
8. Wanklyn P, Forster A, Young J. Hemiplegic shoulder pain (hsp): Natural history and investigation of associated features. Disabil Rehabil. 1996;18:497-501.
9. Bender L, McKenna K. Hemiplegic shoulder pain: Defining the problem and its management. Disabil Rehabil. 2001;23:698-705.
10. Van Ouwenaller C, Laplace PM, Chantraine A. Painful shoulder in hemiplegia. Arch Phys Med Rehabil. 1986;67:23-26.
11. Bohannon RW, Larkin PA, Smith MB, Horton MG. Shoulder pain in hemiplegia: Statistical relationship with five variables. Arch Phys Med Rehabil. 1986;67:514-516.
12. Geurts AC, Visschers BA, van Limbeek J, Ribbers GM. Systematic review of aetiology and treatment of post-stroke hand oedema and shoulder-hand syndrome. Scand J Rehabil Med. 2000;32:4-10.
13. Vuagnat H, Chantraine A. Shoulder pain in hemiplegia revisited: Contribution of functional electrical stimulation and other therapies. J Rehabil Med. 2003;35:49-54.
14. Chantraine A, Baribeault A, Uebelhart D, Gremion G. Shoulder pain and dysfunction in hemiplegia: Effects of functional electrical stimulation. Arch Phys Med Rehabil. 1999;80:328-331.
15. Renzenbrink GJ, MJ IJ. Percutaneous neuromuscular electrical stimulation (p-nmes) for treating shoulder pain in chronic hemiplegia. Effects on shoulder pain and quality of life. Clin Rehabil. 2004;18:359-365.
16. Dekker JH, Wagenaar RC, Lankhorst GJ, de Jong BA. The painful hemiplegic shoulder: Effects of intra-articular triamcinolone acetonide. Am J Phys Med Rehabil. 1997;76:43-48.
17. Snels IA, Beckerman H, Twisk JW, Dekker JH, Peter De K, Koppe PA, Lankhorst GJ, Bouter LM. Effect of triamcinolone acetonide injections on hemiplegic shoulder pain: A randomized clinical trial. Stroke. 2000;31:2396-2401.
18. Snels IA, Dekker JH, van der Lee JH, Lankhorst GJ, Beckerman H, Bouter LM. Treating patients with hemiplegic shoulder pain. Am J Phys Med Rehabil. 2002;81:150-160.
19. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395-400.
20. Smith SJ, Ellis E, White S, Moore AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil. 2000;14:5-13.
21. Wang HC, Hsieh LF, Chi WC, Lou SM. Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil. 2002;81:272-278.
22. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type a on disability and carer burden due to arm spasticity after stroke: A randomized double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000;69:217-221.
23. Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, Coxon L. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type a in upper limb spasticity in patients with stroke. Eur J Neurol. 2001;8:559-565.
24. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, Mordaunt JM, Monaghan EP. Botulinum toxin type a in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial. Neurology. 1996;46:1306-1310.
25. Jabbari B, Maher N, Difazio MP. Botulinum toxin a improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med. 2003;4:206-210.
26. Kern U, Martin C, Scheicher S, Muller H. Treatment of phantom pain with botulinum-toxin a. A pilot study. Schmerz. 2003;17:117-124.
27. Ojala T, Arokoski JP, Partanen J. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: A double-blind, randomized, and controlled crossover trial. Clin J Pain. 2006;22:90-96.
28. Wong SM, Hui AC, Tong PY, Poon DW, Yu E, Wong LK. Treatment of lateral epicondylitis with botulinum toxin: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2005;143:793-797.
29. Argoff CE. The use of botulinum toxins for chronic pain and headaches. Curr Treat Options Neurol. 2003;5:483-492.
30. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain. 1994;59:65-69.
31. Royal MA. Botulinum toxins in pain management. Phys Med Rehabil Clin N Am. 2003;14:805-820.
32. Liu HT, Tsai SK, Kao MC, Hu JS. Botulinum toxin a relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med. 2006;7:89-91.
33. Luvisetto S, Marinelli S, Cobianchi S, Pavone F. Anti-allodynic efficacy of Botulinum neurotoxin A in a model of neuropathic pain. Neuroscience. 2007;145:1-4.
34. Smith HS, Audette J, Royal MA. Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain. 2002;18:S147-S154.
35. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. 2004;251 Suppl 1:I1-I7.
36. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin a reduces formalin-induced pain. Pain. 2004;107:125-133.
37. Kim DY, Oh BM, Paik NJ. Central effect of botulinum toxin type a in humans. Int J Neurosci. 2006;116:667-680.
38. Montecucco C, Schiavo G, Rossetto O. The mechanism of action of tetanus and botulinum neurotoxins. Arch Toxicol Suppl. 1996;18:342-354.
39. Shone CC, Melling J. Inhibition of calcium-dependent release of noradrenaline from pc12 cells by botulinum type-a neurotoxin. Long-term effects of the neurotoxin on intact cells. Eur J Biochem. 1992;207:1009-1016.
40. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to clostridium botulinum neurotoxins. Toxicon. 2000;38:245-258.
41. McMahon HT, Foran P, Dolly JO, Verhage M, Wiegant VM, Nicholls DG. Tetanus toxin and botulinum toxins type a and b inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. J Biol Chem. 1992;267:21338-21343.
42. Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K. Presynaptic effects of botulinum toxin type a on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44:106-109.
43. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol. 2004;172:1529-1532.
44. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type a: Implications for migraine therapy. Headache. 2004;44:35-42.
45. World medical association declaration of helsinki: Ethical principles for medical research involving human subjects. JAMA. 2000;284:3043-3045.
46. Chang YW, Hughes RE, Su FC, Itoi E, An KN. Prediction of muscle force involved in shoulder internal rotation. J Shoulder Elbow Surg. 2000;9:188-195.
47. Braun RM, West F, Mooney V, Nickel VL, Roper B, Caldwell C. Surgical treatment of the painful shoulder contracture in the stroke patient. J Bone Joint Surg Am. 1971;53:1307-1312.
48. Yelnik AP, Colle FM, Bonan IV, Vicaut E. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: A randomized, double-blind, placebo-controlled study of botulinum toxin a. J Neurol Neurosurg Psychiatry. 2007;78:845-848.
49. Gagliese L, Weizblit N, Ellis W, Chan VW. The measurement of postoperative pain: A comparison of intensity scales in younger and older surgical patients. Pain. 2005;117:412-420.
50. Komiyama O, De Laat A. Tactile and pain thresholds in the intra- and extra-oral regions of symptom-free subjects. Pain. 2005;115:308-315.
51. Koman LA, Mooney JF 3rd, Smith BP, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with botulinum-a toxin: Report of a preliminary, randomized, double-blind trial. J Pediatr Orthop. 1994;14:299-303.
52. Slawek J, Klimont L. Functional improvement in cerebral palsy patients treated with botulinum toxin a injections - preliminary results. Eur J Neurol. 2003;10:313-317.
53. Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The poststroke hemiplegic patient. 1. A method for evaluation of physical performance. Scand J Rehabil Med. 1975;7:13-31.
54. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206-207.
55. Unnebrink K, Windeler J. Intention-to-treat: Methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med. 2001;20:3931-3946.
56. Snels IA, Beckerman H, Lankhorst GJ, Bouter LM. Treatment of hemiplegic shoulder pain in the Netherlands: Results of a national survey. Clin Rehabil. 2000;14:20-27.